U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency) ...

"The FDA’s approval for pediatric patients 7 to <12 years of age is reflective of Bayer’s commitment to the hemophilia A community and underscores our commitment to supporting families through ...

Bayer continues to prioritize support for the hemophilia community, and we are excited to offer Jivi as a treatment option for patients and their families. About Jivi® [antihemophilic factor ...

World Hemophillia Day 2025: Today April 17, is World Hemophilia Day, marking a rare genetic disorder where blood doesn't clot properly. In toddlers, early signs like frequent bruising, prolonged ...

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

For this article, Jim Kling interviewed Mark Kay, a professor of pediatrics and genetics, and director of the Human Gene Therapy program at Stanford University, Stanford, Calif., and pediatrics ...

Hemophilia B is a rare, X-linked disorder that predisposes patients to recurrent episodes of bleeding. In severe cases, bleeding can be so significant as to be life-threatening, especially if ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.

Lynn Malec, MD, joined us to discuss the phase 3 XTEND-Kids study of ALTUVIIIO in pediatric patients with hemophilia A.